Newsweek reports:
Pharmaceutical manufacturer Johnson & Johnson announced Friday that early trials of a COVID-19 vaccine showed a 98 percent success rate in showing a boost in the immune system. According to research from Johnson & Johnson, the vaccine enabled 98 percent of those who took it to create antibodies that fight off the coronavirus infection. Those neutralizing antibodies were present 29 days after receiving the vaccination…
Currently, four U.S. vaccines are in the final trial stages. Vaccines from other pharmaceutical companies such as Pfizer and Moderna are administered in two doses while the Johnson & Johnson vaccine only requires one.
“Based on the current results, Johnson & Johnson on Wednesday kicked off a final 60,000-person trial,” reports Reuters, “which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3 trial by the end of the year or early next year.”
of this story at Slashdot.
Source:: Slashdot